Pharmacogenetic information in Swiss drug labels - a systematic analysis

被引：17

作者：

Jeiziner, C. ^{[1
]}

Suter, K. ^{[2
]}

Wernli, U. ^{[1
]}

Barbarino, J. M. ^{[3
]}

Gong, L. ^{[3
]}

Whirl-Carrillo, M. ^{[3
]}

Klein, T. E. ^{[3
,4
]}

Szucs, T. D. ^{[2
]}

Hersberger, K. E. ^{[1
]}

Meyer zu Schwabedissen, H. E. ^{[5
]}

机构：

[1] Univ Basel, Dept Pharmaceut Sci, Pharmaceut Care Res Grp, CH-4001 Basel, Switzerland

[2] Univ Basel, European Ctr Pharmaceut Med, Fac Med, CH-4056 Basel, Switzerland

[3] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA

[4] Stanford Univ, Dept Med, Stanford, CA 94305 USA

[5] Univ Basel, Dept Pharmaceut Sci, Biopharm, CH-4056 Basel, Switzerland

来源：

PHARMACOGENOMICS JOURNAL | 2021年 / 21卷 / 04期

关键词：

CONSORTIUM CPIC GUIDELINE; BIOMARKER INFORMATION; CYP2D6; VARIANTS; GENE; HYPERSENSITIVITY; POLYMORPHISMS; GENOTYPES; HLA; US;

D O I：

10.1038/s41397-020-00195-4

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Implementation of pharmacogenetics (PGx) and individualization of drug therapy is supposed to obviate adverse drug reactions or therapy failure. Health care professionals (HCPs) use drug labels (DLs) as reliable information about drugs. We analyzed the Swiss DLs to give an overview on the currently available PGx instructions. We screened 4306 DLs applying natural language processing focusing on drug metabolism (pharmacokinetics) and we assigned PGx levels following the classification system of PharmGKB. From 5979 hits, 2564 were classified as PGx-relevant affecting 167 substances. 55% (n = 93) were classified as "actionable PGx". Frequently, PGx information appeared in the pharmacokinetics section and in DLs of the anatomic group "nervous system". Unstandardized wording, appearance of PGx information in different sections and unclear instructions challenge HCPs to identify and interpret PGx information and translate it into practice. HCPs need harmonization and standardization of PGx information in DLs to personalize drug therapies and tailor pharmaceutical care.

引用

页码：423 / 434

页数：12

共 45 条

[1] The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine
Bahar, Muh. Akbar
Kamp, Jasper
Borgsteede, Sander D.
Hak, Eelko
Wilffert, Bob
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (12) : 2704 - 2715
[2] Pharmacogenetics and Predictive Testing of Drug Hypersensitivity Reactions
Boehm, Ruwen
Cascorbi, Ingolf
[J]. FRONTIERS IN PHARMACOLOGY, 2016, 7
[3] ABCB1 gene variants and antidepressant treatment outcome: A meta-analysis
Breitenstein, Barbara
Brueckl, Tanja Maria
Ising, Marcus
Mueller-Myhsok, Bertram
Holsboer, Florian
Czamara, Darina
[J]. AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2015, 168 (04) : 274 - 283
[4] The role of pharmacogenomics in adverse drug reactions
Cacabelos, Ramon
Cacabelos, Natalia
Carril, Juan C.
[J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (05) : 407 - 442
[5] Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians
Chen, Chun-Bing
Hsiao, Yi-Hsin
Wu, Tony
Hsih, Mo-Song
Tassaneeyakul, Wichittra
Jorns, Teekayu P.
Sukasem, Chonlaphat
Hsu, Chien-Ning
Su, Shih-Chi
Chang, Wan-Chun
Hui, Rosaline Chung-Yee
Chu, Chia-Yu
Chen, Yi-Ju
Wu, Ching-Ying
Hsu, Chao-Kai
Chiu, Tsu-Man
Sun, Pei-Lun
Lee, Hua-En
Yang, Chin-Yi
Kao, Pei-han
Yang, Chih-Hsun
Ho, Hsin-Chun
Lin, Jing-Yi
Chang, Ya-Ching
Chen, Ming-Jing
Lu, Chun-Wei
Ng, Chau Yee
Kuo, Kang-Ling
Lin, Chien-yio
Yang, Ching-Sheng
Chen, Ding-Ping
Chang, Pi-Yueh
Wu, Tsu-Lan
Lin, Yu-Jr
Weng, Yi-Ching
Kuo, Tseng-tong
Hung, Shuen-Iu
Chung, Wen-Hung
[J]. NEUROLOGY, 2017, 88 (01) : 78 - 86
[6] Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan
Chen, Pei
Lin, Juei-Jueng
Lu, Chin-Song
Ong, Cheung-Ter
Hsieh, Peiyuan F.
Yang, Chih-Chao
Tai, Chih-Ta
Wu, Shey-Lin
Lu, Cheng-Hsien
Hsu, Yung-Chu
Yu, Hsiang-Yu
Ro, Long-Sun
Lu, Chung-Ta
Chu, Chun-Che
Tsai, Jing-Jane
Su, Yu-Hsiang
Lan, Sheng-Hsing
Sung, Sheng-Feng
Lin, Shu-Yi
Chuang, Hui-Ping
Huang, Li-Chen
Chen, Ying-Ju
Tsai, Pei-Joung
Liao, Hung-Ting
Lin, Yu-Hsuan
Chen, Chien-Hsiun
Chung, Wen-Hung
Hung, Shuen-Iu
Wu, Jer-Yuarn
Chang, Chi-Feng
Chen, Luke
Chen, Yuan-Tsong
Shen, Chen-Yang
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (12) : 1126 - 1133
[7] Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene-drug pairs across ambulatory care settings
Cicali, Emily J.
Weitzel, Kristin Wiisanen
Elsey, Amanda R.
Orlando, Frank A.
Vinson, Michelle
Mosley, Scott
Smith, D. Max
Davis, Richard
Drum, Lori
Estores, David
Franciosi, James P.
Hagen, Melanie Gross
Jerkins, Gabriel J.
Mercado, Elvira S.
Nainaparampil, Jaison
Padron, Adaixa
Rosenberg, Eric I.
Wright, Ashleigh
Schmidt, Siegfried O.
Mathews, Carol A.
Cavallari, Larisa H.
Johnson, Julie A.
[J]. GENETICS IN MEDICINE, 2019, 21 (10) : 2264 - 2274
[8] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype
Crews, K. R.
Gaedigk, A.
Dunnenberger, H. M.
Klein, T. E.
Shen, D. D.
Callaghan, J. T.
Kharasch, E. D.
Skaar, T. C.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (02) : 321 - 326
[9] Pharmacogenomic Testing for Neuropsychiatric Drugs: Current Status of Drug Labeling, Guidelines for Using Genetic Information, and Test Options
Drozda, Katarzyna
Mueller, Daniel J.
Bishop, Jeffrey R.
[J]. PHARMACOTHERAPY, 2014, 34 (02): : 166 - 184
[10] Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers
Dunnenberger, Henry M.
Crews, Kristine R.
Hoffman, James M.
Caudle, Kelly E.
Broeckel, Ulrich
Howard, Scott C.
Hunkler, Robert J.
Klein, Teri E.
Evans, William E.
Relling, Mary V.
[J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 55, 2015, 55 : 89 - +

← 1 2 3 4 5 →